These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 24419239)

  • 1. Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis.
    Kubota K; Ichinose Y; Scagliotti G; Spigel D; Kim JH; Shinkai T; Takeda K; Kim SW; Hsia TC; Li RK; Tiangco BJ; Yau S; Lim WT; Yao B; Hei YJ; Park K
    Ann Oncol; 2014 Feb; 25(2):529-36. PubMed ID: 24419239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.
    Scagliotti GV; Vynnychenko I; Park K; Ichinose Y; Kubota K; Blackhall F; Pirker R; Galiulin R; Ciuleanu TE; Sydorenko O; Dediu M; Papai-Szekely Z; Banaclocha NM; McCoy S; Yao B; Hei YJ; Galimi F; Spigel DR
    J Clin Oncol; 2012 Aug; 30(23):2829-36. PubMed ID: 22753922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    Kubota K; Yoshioka H; Oshita F; Hida T; Yoh K; Hayashi H; Kato T; Kaneda H; Yamada K; Tanaka H; Ichinose Y; Park K; Cho EK; Lee KH; Lin CB; Yang JC; Hara K; Asato T; Nakagawa K
    J Clin Oncol; 2017 Nov; 35(32):3662-3670. PubMed ID: 28902534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 study.
    Novello S; Scagliotti GV; Sydorenko O; Vynnychenko I; Volovat C; Schneider CP; Blackhall F; McCoy S; Hei YJ; Spigel DR
    J Thorac Oncol; 2014 Aug; 9(8):1154-61. PubMed ID: 25157768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer.
    Blumenschein GR; Kabbinavar F; Menon H; Mok TSK; Stephenson J; Beck JT; Lakshmaiah K; Reckamp K; Hei YJ; Kracht K; Sun YN; Sikorski R; Schwartzberg L;
    Ann Oncol; 2011 Sep; 22(9):2057-2067. PubMed ID: 21321086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience.
    Bass MB; Yao B; Hei YJ; Ye Y; Davis GJ; Davis MT; Kaesdorf BA; Chan SS; Patterson SD
    PLoS One; 2014; 9(10):e108048. PubMed ID: 25314641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
    Patel JD; Socinski MA; Garon EB; Reynolds CH; Spigel DR; Olsen MR; Hermann RC; Jotte RM; Beck T; Richards DA; Guba SC; Liu J; Frimodt-Moller B; John WJ; Obasaju CK; Pennella EJ; Bonomi P; Govindan R
    J Clin Oncol; 2013 Dec; 31(34):4349-57. PubMed ID: 24145346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer.
    Ramalingam SS; Shtivelband M; Soo RA; Barrios CH; Makhson A; Segalla JG; Pittman KB; Kolman P; Pereira JR; Srkalovic G; Belani CP; Axelrod R; Owonikoko TK; Qin Q; Qian J; McKeegan EM; Devanarayan V; McKee MD; Ricker JL; Carlson DM; Gorbunova VA
    J Clin Oncol; 2015 Feb; 33(5):433-41. PubMed ID: 25559798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
    Lara PN; Douillard JY; Nakagawa K; von Pawel J; McKeage MJ; Albert I; Losonczy G; Reck M; Heo DS; Fan X; Fandi A; Scagliotti G
    J Clin Oncol; 2011 Aug; 29(22):2965-71. PubMed ID: 21709202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.
    Govindan R; Szczesna A; Ahn MJ; Schneider CP; Gonzalez Mella PF; Barlesi F; Han B; Ganea DE; Von Pawel J; Vladimirov V; Fadeeva N; Lee KH; Kurata T; Zhang L; Tamura T; Postmus PE; Jassem J; O'Byrne K; Kopit J; Li M; Tschaika M; Reck M
    J Clin Oncol; 2017 Oct; 35(30):3449-3457. PubMed ID: 28854067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer.
    Blumenschein GR; Reckamp K; Stephenson GJ; O'Rourke T; Gladish G; McGreivy J; Sun YN; Ye Y; Parson M; Sandler A
    Clin Cancer Res; 2010 Jan; 16(1):279-90. PubMed ID: 20028752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.
    Zhou C; Wu YL; Chen G; Liu X; Zhu Y; Lu S; Feng J; He J; Han B; Wang J; Jiang G; Hu C; Zhang H; Cheng G; Song X; Lu Y; Pan H; Zheng W; Yin AY
    J Clin Oncol; 2015 Jul; 33(19):2197-204. PubMed ID: 26014294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
    Socinski MA; Bondarenko I; Karaseva NA; Makhson AM; Vynnychenko I; Okamoto I; Hon JK; Hirsh V; Bhar P; Zhang H; Iglesias JL; Renschler MF
    J Clin Oncol; 2012 Jun; 30(17):2055-62. PubMed ID: 22547591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.
    Lynch TJ; Bondarenko I; Luft A; Serwatowski P; Barlesi F; Chacko R; Sebastian M; Neal J; Lu H; Cuillerot JM; Reck M
    J Clin Oncol; 2012 Jun; 30(17):2046-54. PubMed ID: 22547592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer.
    Paz-Ares LG; Biesma B; Heigener D; von Pawel J; Eisen T; Bennouna J; Zhang L; Liao M; Sun Y; Gans S; Syrigos K; Le Marie E; Gottfried M; Vansteenkiste J; Alberola V; Strauss UP; Montegriffo E; Ong TJ; Santoro A;
    J Clin Oncol; 2012 Sep; 30(25):3084-92. PubMed ID: 22851564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.
    von Pawel J; Spigel DR; Ervin T; Losonczy G; Barlesi F; Juhász E; Anderson M; McCall B; Wakshull E; Hegde P; Ye W; Chen D; Chang I; Rhee I; Reck M
    Oncologist; 2018 Jun; 23(6):654-e58. PubMed ID: 29438092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer.
    Reck M; Krzakowski M; Chmielowska E; Sebastian M; Hadler D; Fox T; Wang Q; Greenberg J; Beckman RA; von Pawel J
    Lung Cancer; 2013 Dec; 82(3):441-8. PubMed ID: 24148258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer.
    Satouchi M; Okamoto I; Sakai H; Yamamoto N; Ichinose Y; Ohmatsu H; Nogami N; Takeda K; Mitsudomi T; Kasahara K; Negoro S
    Lung Cancer; 2013 Jul; 81(1):97-101. PubMed ID: 23545279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Diabetes.
    Hirsh V; Ko A; Pilot R; Renschler MF; Socinski MA
    Clin Lung Cancer; 2016 Sep; 17(5):367-374. PubMed ID: 27230605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
    Spigel DR; Luft A; Depenbrock H; Ramlau R; Khalil M; Kim JH; Mayo C; Chao GY; Obasaju C; Natale R
    Clin Lung Cancer; 2017 Sep; 18(5):480-488. PubMed ID: 28365238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.